Silexion Therapeutics has entered a strategic partnership with global therapeutics manufacturer Catalent to optimize and manufacture its innovative cancer treatment SIL204, a breakthrough RNA interference therapy targeting KRAS mutations in pancreatic cancer.
The collaboration will utilize Catalent's advanced Limoges, France facility to develop systemic and intratumoral delivery formulations for SIL204, positioning the therapy for potential human clinical trials in the first half of 2026. Preclinical studies have demonstrated remarkable efficacy, with tumor reductions ranging from 70-80% across multiple pancreatic cancer models.
Unlike existing treatments that target only specific KRAS mutations, Silexion's approach can silence multiple genetic variants present in over 90% of pancreatic cancers. The therapy's unique dual-route strategy—targeting both primary tumors and metastatic spread—represents a significant advancement in precision oncology.
The collaboration arrives at a critical moment in the precision medicine market, which is projected to grow from $102 billion in 2024 to $470 billion by 2034. With pancreatic cancer's notoriously low five-year survival rate of less than 13%, Silexion's technology could potentially revolutionize treatment paradigms for this aggressive disease.
Wall Street analysts have expressed optimism, maintaining a price target that suggests over 500% potential upside. The partnership with Catalent adds credibility to Silexion's development roadmap and positions the company at the forefront of innovative cancer research.
